BRIEF published on 01/27/2026 at 18:05, 6 months ago Theranexus Liquidity Contract Half-Year Review Liquidity Contract PORTZAMPARC Financial Report Theranexus THX Pharma Actions
BRIEF published on 01/20/2026 at 18:05, 6 months 7 days ago THX Pharma unveils its 2026 financial calendar Euronext Paris Financial Agenda Biopharmaceutical 2026 THX Pharma
BRIEF published on 01/20/2026 at 18:05, 6 months 7 days ago THX Pharma Reveals 2026 Financial Schedule Financial Calendar Neurological Diseases Market Communication 2026 Announcements THX Pharma
PRESS RELEASE published on 01/20/2026 at 18:00, 6 months 7 days ago THX Pharma Announces its 2026 Financial Calendar THX Pharma (Theranexus) announces financial communication agenda for 2026, focusing on rare neurological diseases treatments. Company listed on Euronext Growth Paris Euronext Growth Paris Financial Communication Theranexus Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 6 months 19 days ago THX Pharma Releases Shareholder Letter Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 6 months 19 days ago Publication of the letter to shareholders by Theranexus Shareholders Neuroscience Rare Diseases Theranexus Drugs
PRESS RELEASE published on 01/08/2026 at 18:00, 6 months 19 days ago THX Pharma announces the publication of its letter to shareholders THX Pharma (Theranexus) announces the publication of its letter to shareholders, highlighting treatments for rare neurological diseases and upcoming drug commercialization. Forward-looking statements included Forward-looking Statements Theranexus Neurological Diseases THX Pharma Drug Commercialization
BRIEF published on 01/07/2026 at 08:05, 6 months 20 days ago THX Pharma appoints Julien Veys as Deputy General Manager Business Strategy Appointment THX Pharma Julien Veys Neurological Medications
BRIEF published on 01/07/2026 at 08:05, 6 months 20 days ago THX Pharma Names Julien Veys as Deputy CEO Rare Neurological Diseases THX Pharma Julien Veys Appointment Theranexus Strategy Pharmaceutical Commercialization
PRESS RELEASE published on 01/07/2026 at 08:00, 6 months 20 days ago THX Pharma Announces the Appointment of Julien Veys as Deputy Chief Executive Officer THX Pharma appoints Julien Veys as Deputy CEO to drive new strategy focusing on regulatory approval and commercialization of medicines for rare neurological diseases Regulatory Approval Deputy CEO Neurological Diseases THX Pharma Julien Veys
Published on 07/28/2026 at 03:05, 3 hours 29 minutes ago Mining Exploration Entity or Oil And Gas Exploration Entity Quarterly Cash Flow Report
Published on 07/28/2026 at 03:00, 3 hours 34 minutes ago Storm Announces Closing of Oversubscribed $2.95M Private Placement
Published on 07/27/2026 at 14:00, 16 hours 34 minutes ago Silver Storm Announces First Concentrate Shipment from La Parrilla
Published on 07/27/2026 at 13:30, 17 hours 4 minutes ago International Battery Metals Announces CEO Transition
Published on 07/28/2026 at 06:00, 34 minutes ago Schlatter strengthens its management team for the next phase of the company’s development
Published on 07/27/2026 at 23:05, 7 hours 29 minutes ago Quantinuum to Report Second Quarter Financial Results on August 11, 2026
Published on 07/27/2026 at 22:45, 7 hours 48 minutes ago EQS-Adhoc: Hypoport SE: Gross profit growth and significant increase in EBIT in H1/26
Published on 07/27/2026 at 21:15, 9 hours 19 minutes ago Xryma Plc announces the upcoming launch of XrymaCoin (XREUR), the regulated euro stablecoin designed to work like money
Published on 07/27/2026 at 18:00, 12 hours 34 minutes ago Saint-Gobain accelerates in Asia with two targeted acquisitions
Published on 07/27/2026 at 08:29, 22 hours 5 minutes ago FREY H1 2026: a platform geared towards a new phase of growth
